Azithromycin Tablet 250mg

• Customization: Available
• Application: Internal Medicine
• Usage Mode: For oral administration
• Suitable for: Elderly, Adult
• State: Solid
• Shape: Tablet
• Type: Organic Chemicals
• Pharmaceutical Technology: Chemical Synthesis
• Drug Reg./Approval No.: SL12345
• Drug Ad Approval No.: SL12345
• Registration Dossiers: Available
• Quality Standard: Bp or USP
• Test Report: Available
• Transport Package: 10 Tablet Per Box, 200 Box Per Carton
• Specification: 250mg
• Trademark: Shenglu
• Origin: China
• HS Code: 300490
• Production Capacity: 1 Billion Per Year

Product Description

Azithromycin tablet 250mg

 Azithromycin tablet 250mg
Composition:
Each film -coated tablet contains 250mg Azithromycin  

Product Name:	Azithromycin tablet 250mg
Strength:	250mg
Dosage Form:	For oral Use
Packing:	3X 10 per box
Route of Administration:	For oral Use
Pack Insert/Leaflet:	PIL (Patient Information Leaflet), SmPC (Summary Product Characteristics)
Regulatory Documents:	COA, MOA, COPP, FSC, Stability Studies, GMP, CTD Dossier
Storage:	Store below 25°C. Protect from Light. Do not freeze.

WHY Choose Shandong Shenglu Pharmaceutical  ? 

Shandong Shenglu Pharmaceutical Co., LTD., located at the intersection of Sihe Road North and 327 National Road North, Surabaya County, formerly known as Shandong Sishui Pharmaceutical Factory, was founded in 1987, is a comprehensive pharmaceutical preparation manufacturer approved by Shandong Provincial Health Department Luwei Medicine Word (88) No. 34.

 At present, the company has total assets of 267 million yuan and covers an area of 120,000 square meters. The existing fixed staff of more than 220 people, including production, quality inspection, research and development, equipment and other professional and technical personnel 130 people, at the same time has a professional marketing team of more than 30 people. The company's main product dosage forms are small capacity injection, tablet, hard capsule, powder injection (export), by the national registration approval number of 59. It has the annual production capacity of 1 billion small-volume injections, 1 billion tablets, 500 million capsules and 100 million powder-injection.